234082-06-5

Basic information

• Product Name: ethyl 4-{cis-3,5-dimethyl-4-(pyrimidin-2-yl)piperazin-1-yl}benzoate
• Synonyms: ethyl 4-{cis-3,5-dimethyl-4-(pyrimidin-2-yl)piperazin-1-yl}benzoate
• CAS NO: 234082-06-5
• Molecular Weight: 340.425
• Mol File: 234082-06-5.mol

Chemical Properties

• CAS DataBase Reference: ethyl 4-{cis-3,5-dimethyl-4-(pyrimidin-2-yl)piperazin-1-yl}benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-{cis-3,5-dimethyl-4-(pyrimidin-2-yl)piperazin-1-yl}benzoate(234082-06-5)
• EPA Substance Registry System: ethyl 4-{cis-3,5-dimethyl-4-(pyrimidin-2-yl)piperazin-1-yl}benzoate(234082-06-5)

Safety Data

• Hazardous Substances Data: 234082-06-5(Hazardous Substances Data)

Upstream product

• 234082-05-4 ethyl 4-((3R,5S)-3,5-dimethylpiperazin-1-yl)benzoate 
• 4595-60-2 2-bromopyrimidine 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 451-46-7 4-fluorobenzoic acid ethyl ester 

Downstream Products

• 234082-07-6 4-{cis-3,5-dimethyl-4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid 

Relevant articles and documents

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/ αIIbβ3 dual antagonistic activity

In order to generate novel compounds with integrin α vβ3-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective αIIbβ3 antagonists, replacement of piperazine with piperidine furnished a potent αvβ3/ αIIbβ3 dual antagonist. Structure-activity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists.

Phenylpiperazine derivatives as integrin αvβ3 antagonists

An objective of the present invention is to provide compounds having integrin αvβ3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin αvβ3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.